Literature DB >> 15913469

The clinical diagnosis of ventilator-associated pneumonia.

Michael S Niederman1.   

Abstract

There has long been a controversy about whether to use a clinical or microbiologic approach to diagnose ventilator-associated pneumonia (VAP) and about which approach to use in managing patients. Although the clinical approach has often been criticized, a number of recent studies have shown that it is possible to use such an approach to effectively manage patients. This approach involves using all available clinical data to define the presence of pneumonia and then to initiate empiric therapy in a timely fashion, based on therapy guidelines, modified by local microbiologic data. Often the clinical diagnosis is made using the clinical pulmonary infection score, and this tool can be very accurate, especially if it incorporates a Gram stain of a lower-respiratory-tract sample. Once the clinical diagnosis of VAP is made, all patients should have a tracheal aspirate collected for culture, followed by prompt initiation of therapy. Using a clinical approach to management, the key decision point is not whether to start antibiotics, but whether to continue them at day 2-3. This requires serial clinical evaluation to define whether a response to empiric therapy has occurred. Based on this assessment, in conjunction with the results of tracheal aspirate cultures, therapy can be either modified or continued. A number of studies have shown that the clinical approach leads to a large number of patients receiving adequate empiric therapy, while still permitting de-escalation of antibiotic regimens, along with short durations of therapy. Thus a clinical approach to management can be successful in allowing for effective management of VAP, without promoting the unnecessary use of broad-spectrum antimicrobial therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15913469

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  6 in total

1.  Serial changes in soluble triggering receptor expressed on myeloid cells in the lung during development of ventilator-associated pneumonia.

Authors:  Rogier M Determann; Julian L Millo; Sébastien Gibot; Johanna C Korevaar; Margreeth B Vroom; Tom van der Poll; Christopher S Garrard; Marcus J Schultz
Journal:  Intensive Care Med       Date:  2005-09-30       Impact factor: 17.440

2.  Effect of multimodality chest physiotherapy in prevention of ventilator-associated pneumonia: A randomized clinical trial.

Authors:  Renu B Pattanshetty; G S Gaude
Journal:  Indian J Crit Care Med       Date:  2010-04

3.  Ventilator associated pneumonia in critically-ill neonates admitted to neonatal intensive care unit, zagazig university hospitals.

Authors:  Mohamed A Badr; Yasser F Ali; Ehab A M Albanna; Mohamed R Beshir; Gahda E Amr
Journal:  Iran J Pediatr       Date:  2011-12       Impact factor: 0.364

4.  Rapid, cost-effective, sensitive and quantitative detection of Acinetobacter baumannii from pneumonia patients.

Authors:  B Nomanpour; A Ghodousi; A Babaei; Hr Abtahi; M Tabrizi; Mm Feizabadi
Journal:  Iran J Microbiol       Date:  2011-12

5.  The tracheal tube: gateway to ventilator-associated pneumonia.

Authors:  Parjam S Zolfaghari; Duncan L A Wyncoll
Journal:  Crit Care       Date:  2011-09-29       Impact factor: 9.097

6.  Elevated Plasma Matrix Metalloproteinase-9 and Its Correlations with Severity of Disease in Patients with Ventilator-Associated Pneumonia.

Authors:  Yia-Ting Li; Yao-Chen Wang; Hsiang-Lin Lee; Min-Chi Lu; Shun-Fa Yang
Journal:  Int J Med Sci       Date:  2016-07-26       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.